Aeglea Competitors

Delisted . USA . 
Stock . Aeglea Bio Therapeutics
AGLEDelisted Stock  USD 0.59  0.01  1.72%   
Aeglea Bio Therapeutics competes with Edgewise Therapeutics, Ikena Oncology, Design Therapeutics, Xilio Development, and Eliem Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Aeglea Bio competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Aeglea Bio to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Aeglea Bio competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.590.590.59
Details
Intrinsic
Valuation
LowRealHigh
0.420.420.65
Details
Naive
Forecast
LowNextHigh
0.550.550.55
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.030.360.75
Details

Aeglea Bio Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Aeglea Bio and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Aeglea and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Aeglea Bio Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ANGN
+ 0.9
LABP
LABP
+ 0.81
EWTX
ANGN
+ 0.71
EWTX
LABP
+ 0.62
XLO
ANGN
+ 0.57
XLO
NAVB
+ 0.57
EFTR
  
High negative correlations   
ANGN
- 0.84
ELYM
LABP
- 0.8
ELYM
ELYM
- 0.79
EWTX
NAVB
- 0.73
EWTX
ELYM
- 0.6
XLO
NAVB
- 0.52
LABP

Risk-Adjusted Indicators

There is a big difference between Aeglea Stock performing well and Aeglea Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Aeglea Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EWTX  3.63  0.57  0.21  0.30  3.05 
(4.27)
 6.65 
(5.51)
 61.02 
IKNA  1.08 (0.05)(0.06) 0.01  1.38 
(1.50)
 1.81 
(1.74)
 13.50 
DSGN  4.16 (0.01) 0.02  0.10  5.44 
(4.54)
 9.61 
(8.21)
 35.31 
XLO  5.27  0.31  0.03  1.45  6.17 
(6.56)
 10.10 
(10.99)
 57.76 
ELYM  3.92 (0.89) 0.00 (4.85) 0.00 
 0.00 
 6.21 
(9.35)
 34.87 
EFTR  7.57 (4.70) 0.00 (3.44) 0.00 
 0.00 
 8.70 
(27.78)
 88.91 
LABP  3.55  0.56  0.10 (3.18) 3.81 
(3.77)
 8.58 
(7.05)
 19.47 
APGN  5.12  0.02  0.00  0.13  5.50 
(7.45)
 7.89 
(11.11)
 58.79 
NAVB  6.04 (1.00) 0.00  1.02  0.00 
 0.00 
 12.50 
(12.50)
 40.40 
ANGN  5.04  0.77  0.13  0.81  5.44 
(5.75)
 11.55 
(7.70)
 42.18 
All Fundamental Data

Aeglea Bio Competitive Analysis

The better you understand Aeglea Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Aeglea Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Aeglea Bio's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AGLE EWTX IKNA DSGN XLO ELYM EFTR LABP APGN NAVB
 1.72 
 0.59 
Aeglea
 0.69 
 32.20 
Edgewise
 1.16 
 1.71 
Ikena
 0.90 
 5.62 
Design
 3.26 
 0.89 
Xilio
 2.60 
 3.00 
Eliem
 30.00 
 0.13 
Effector
 3.60 
 4.02 
Landos
 2.27 
 0.43 
Apexigen
 9.45 
 0.1 
Navidea
Market Volatility
(90 Days Market Risk)
Very steady
Somewhat reliable
Somewhat reliable
Unstable
Dangerous
Very risky
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
OK
Very Weak
Insignificant
Insignificant
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Below Average
Average
Low
Very High
Dangerous
Dangerous
Dangerous
Dangerous
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Hold
Strong Hold
Strong Hold
Cautious Hold
Strong Hold
Not Rated
Not Rated
Not Rated
Not Rated
Current Ratio
4.65
27.49
6.98
48.96
9.17
17.48
1.79
8.91
1.24
0.22
Net Asset
71.14 M
340.04 M
192.09 M
289.64 M
60.93 M
110.47 M
20.54 M
38.04 M
22.86 M
4.37 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(84.78 M)
(112.81 M)
(74.4 M)
(66.33 M)
(73.8 M)
(40.27 M)
(33.73 M)
(22.73 M)
(32.58 M)
(14.05 M)
Operating Margin
-94.85
N/A
-97.55
N/A
-6.54
N/A
N/A
N/A
N/A
N/A
Current Valuation
228.21 M
2.54 B
(46.15 M)
63.83 M
(12.4 M)
122.66 M
(4.52 M)
42.67 M
205.33 K
3.5 M
Price To Book
0.35
6.19
0.62
1.25
1.93
1.56
13.38
2.11
2.32
8.16
Retained Earnings
(425.62 M)
(244.76 M)
(282.38 M)
(177.63 M)
(325.51 M)
(155.98 M)
(179.38 M)
(155.36 M)
(176.79 M)
(388 M)
Current Asset
38.29 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
12.58 M
Beta
2.57
0.15
0.49
1.83
-0.2
-0.35
0.83
0.14
3.62
1.5
Number Of Employees
69
108
14
54
73
9
14
19
11
11
Shares Outstanding
4.05 M
94.69 M
48.26 M
56.62 M
43.96 M
67.06 M
4.7 M
3.13 M
24.86 M
100.08 M
Cash Flow From Operations
(80.14 M)
(91.95 M)
(79.74 M)
(58.56 M)
(68.62 M)
(20.6 M)
(29.55 M)
(20.48 M)
(30.69 M)
(8.99 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
4.63 M
5.41 M
10.74 M
3.05 M
11.46 M
349 K
19.45 M
27 K
106 K
2.43 M
Return On Equity
-2.81
-0.32
-0.37
-0.18
-1.71
-0.38
-9.47
-0.71
-15.98
-11.0
Z Score
-5.56
N/A
N/A
N/A
N/A
N/A
N/A
N/A
38.91
N/A
Return On Asset
-0.42
-0.22
-0.22
-0.14
-0.53
-0.25
-0.83
-0.39
-0.89
-1.22
Number Of Shares Shorted
128.62 K
7.29 M
129.88 K
2.59 M
396.08 K
1.15 M
91.62 K
1.43 K
64.45 K
2.69 M
Book Value Per Share
-60.61
5.18
2.78
4.46
0.48
3.33
0.21
7.43
-0.093
-0.011
Current Liabilities
2.52 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6.18 M
Total Asset
71.14 M
340.04 M
192.09 M
289.64 M
60.93 M
110.47 M
20.54 M
38.04 M
22.86 M
4.37 M
Debt To Equity
0.07
0.007
0.036
0.011
0.14
0.004
1.03
N/A
0.054
1.2
Short Ratio
2.84
7.56
3.02
16.31
1.36
4.07
0.97
0.08
1.72
0.52
Target Price
17.5
43.17
3.0
7.0
4.5
4.5
11.0
12.71
0.64
5.0
Shares Owned By Institutions
97.6
99.54
63.58
56.9
33.5
77.67
23.71
52.04
13.54
1.5
Market Capitalization
45.59 M
3.03 B
83.49 M
315.38 M
40.44 M
346.03 M
846.79 K
71.68 M
9.57 M
8.04 M
Price To Earning
-2.41
3.45
3.89
N/A
N/A
N/A
1.03
N/A
N/A
0.53
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
4.08
N/A
126.69
22642.01
8.75
N/A
69.65
2.37
N/A
84.14
Net Income
(83.81 M)
(100.16 M)
(68.17 M)
(66.86 M)
(76.4 M)
(35.12 M)
(35.81 M)
(21.93 M)
(32.07 M)
(15.18 M)
Earnings Per Share
-74.15
-1.5
-1.23
-0.85
-1.55
-2.22
-12.57
-4.0
-1.71
-0.39
Shares Owned By Insiders
2.4
0.46
10.5
36.45
40.92
10.38
2.9
9.88
8.81
35.43
Revenue
2.33 M
N/A
9.16 M
N/A
N/A
N/A
N/A
N/A
N/A
65.65 K
Working Capital
47.6 M
310.23 M
164.46 M
274.96 M
103.38 M
107.42 M
(5.96 M)
31.79 M
4.73 M
(6.74 M)
Cash And Equivalents
73.68 M
248.4 M
192.81 M
359.38 M
159.41 M
122.95 M
41.04 M
55.75 M
21.62 M
328.01 K
Cash Per Share
1.2
4.99
5.32
6.45
5.82
4.63
0.99
1.38
1.01
0.01
Gross Profit
(262 K)
N/A
(48.7 M)
(48.61 M)
(56.77 M)
N/A
(19.76 M)
18 M
N/A
(119.3 K)
Day Typical Price
0.6
32.23
1.71
5.63
0.9
3.11
0.12
4.08
0.44
0.1
Accumulation Distribution
0.0645
10358.46
760.28
4762.81
12185.03
0.1
0.59
0.0794
0.11
0.11
Market Facilitation Index
0.04
0.0
0.0
0.0
N/A
0.34
0.1
0.34
0.05
0.012
Daily Balance Of Power
0.25
0.2292
(0.50)
0.1515
(0.50)
(0.24)
0.3
(0.44)
(0.20)
(0.87)
Period Momentum Indicator
0.01
0.22
(0.02)
0.05
(0.03)
(0.08)
0.03
(0.15)
(0.01)
(0.01)
Rate Of Daily Change
1.02
1.01
0.99
1.01
0.97
0.97
1.3
0.96
0.98
0.91
Day Median Price
0.6
32.24
1.71
5.64
0.9
3.17
0.12
4.11
0.44
0.1
Price Action Indicator
(0.01)
0.07
(0.01)
0.01
(0.03)
(0.21)
0.025
(0.17)
(0.02)
(0.01)
Coefficient Of Variation
823.83
872.73
12024.92
2262.35
2316.93
(628.57)
(333.16)
842.41
8455.47
(762.99)
Mean Deviation
11.03
3.63
1.08
4.16
5.27
3.92
7.57
3.55
5.12
6.04
Jensen Alpha
4.95
0.5719
(0.05)
(0.01)
0.3107
(0.89)
(4.70)
0.5551
0.0246
(1.00)
Total Risk Alpha
(0.37)
(0.13)
(0.22)
(0.51)
(0.70)
(1.57)
(6.55)
(0.06)
(1.05)
(2.20)
Sortino Ratio
0.542
0.2097
(0.06)
0.0245
0.0328
N/A
N/A
0.0974
(0.0009)
N/A
Downside Variance
75.23
13.2
2.91
34.95
50.83
N/A
N/A
20.3
43.89
N/A
Standard Deviation
39.63
7.6
1.7
5.75
7.96
5.39
15.18
4.62
8.75
8.36
Kurtosis
62.85
39.38
7.14
1.81
7.56
2.45
17.04
0.0588
12.89
0.7251
Potential Upside
12.5
6.65
1.81
9.61
10.1
6.21
8.7
8.58
7.89
12.5
Treynor Ratio
(3.27)
0.2961
0.0074
0.0974
1.45
(4.85)
(3.44)
(3.18)
0.1349
1.02
Maximum Drawdown
331.23
61.02
13.5
35.31
57.76
34.87
88.91
19.47
58.79
40.4
Variance
1570.27
57.83
2.9
33.09
63.35
29.09
230.42
21.33
76.64
69.93
Market Risk Adjusted Performance
(3.26)
0.3061
0.0174
0.1074
1.46
(4.84)
(3.43)
(3.17)
0.1449
1.03
Risk Adjusted Performance
0.1024
0.0964
0.0119
0.0424
0.042
(0.11)
(0.22)
0.0989
0.0181
(0.09)
Skewness
7.84
5.54
0.8595
(0.15)
1.57
0.1305
(3.83)
0.2863
2.85
0.2409
Semi Deviation
4.13
3.05
1.38
5.44
6.17
N/A
N/A
3.81
5.5
N/A
Information Ratio
0.1186
0.1002
(0.06)
0.0252
0.0294
(0.18)
(0.31)
0.095
(0.0007)
(0.14)
Value At Risk
(7.14)
(5.51)
(1.74)
(8.21)
(10.99)
(9.35)
(27.78)
(7.05)
(11.11)
(12.50)
Expected Short fall
(28.79)
(4.27)
(1.50)
(4.54)
(6.56)
N/A
N/A
(3.77)
(7.45)
N/A
Downside Deviation
8.67
3.63
1.7
5.91
7.13
N/A
N/A
4.51
6.62
N/A
Semi Variance
17.07
9.29
1.9
29.55
38.11
N/A
N/A
14.54
30.2
N/A

Aeglea Bio Competition Performance Charts

Five steps to successful analysis of Aeglea Bio Competition

Aeglea Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Aeglea Bio Therapeutics in relation to its competition. Aeglea Bio's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Aeglea Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Aeglea Bio's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Aeglea Bio Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Aeglea Bio position

In addition to having Aeglea Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Materials ETFs Thematic Idea Now

Materials ETFs
Materials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Materials ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Materials ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Other Consideration for investing in Aeglea Stock

If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY